PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+33.39%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$1.75B
AUM Growth
+$1.75B
(+25%)
Cap. Flow
+$113M
Cap. Flow
% of AUM
6.45%
Top 10 Holdings %
Top 10 Hldgs %
46.67%
Holding
235
New
45
Increased
31
Reduced
38
Closed
62
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$50.5M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$26.9M |
| 3 |
Evolent Health
EVH
|
$25.3M |
| 4 |
RDUS
Radius Health, Inc.
RDUS
|
$25M |
| 5 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
$24.5M |
Top Sells
| 1 |
TSRO
TESARO, Inc.
TSRO
|
$68.8M |
| 2 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
$39.5M |
| 3 |
Sarepta Therapeutics
SRPT
|
$29.6M |
| 4 |
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
|
$23.3M |
| 5 |
ACOR
Acorda Therapeutics, Inc.
ACOR
|
$13.5M |
Sector Composition
| 1 | Healthcare | 93.5% |
| 2 | Consumer Discretionary | 0.07% |
| 3 | Industrials | 0.03% |
| 4 | Technology | 0.03% |
| 5 | Energy | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$13.8B
| $146M | 8.3% | 3,366,530 +50,007 | +2% | +$2.17M |
|
|
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $142M | 8.1% | 3,858,978 +730,000 | +23% | +$26.9M |
|
3
Amicus Therapeutics
FOLD
$2.34B
| $123M | 7.03% | 17,296,672 | – | – |
|
|
ARAV
4
DELISTED
Aravive, Inc. Common Stock
ARAV
| $94.1M | 5.36% | 4,407,317 +253,632 | +6% | +$5.42M |
|
|
LJPC
5
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $63.9M | 3.64% | 2,139,274 +820,000 | +62% | +$24.5M |
|
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $56.6M | 3.22% | 1,103,475 +985,000 | +831% | +$50.5M |
|
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $52.4M | 2.99% | 1,771,029 -998,800 | -36% | -$29.6M |
|
8
Travere Therapeutics
TVTX
$1.56B
| $51.8M | 2.95% | 2,807,525 +120,113 | +4% | +$2.22M |
|
|
NXTM
9
DELISTED
NxStage Medical Inc.
NXTM
| $48.8M | 2.78% | 1,818,189 -109,800 | -6% | -$2.95M |
|
10
Xencor
XNCR
$580M
| $38.4M | 2.19% | 1,607,018 -178,000 | -10% | -$4.26M |
|
11
Aclaris Therapeutics
ACRS
$209M
| $37.6M | 2.14% | 1,260,847 | – | – |
|
|
TSRO
12
DELISTED
TESARO, Inc.
TSRO
| $37.1M | 2.11% | 241,028 -446,965 | -65% | -$68.8M |
|
|
VBIV
13
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $36M | 2.05% | 6,565,843 | – | – |
|
|
RDUS
14
DELISTED
Radius Health, Inc.
RDUS
| $35.2M | 2.01% | 910,872 +647,000 | +245% | +$25M |
|
|
AVXS
15
DELISTED
AveXis, Inc. Common Stock
AVXS
| $34.1M | 1.94% | 448,501 -25,030 | -5% | -$1.9M |
|
|
16
Evolent Health
EVH
$1.12B
| $32.2M | 1.83% | 1,444,500 +1,136,700 | +369% | +$25.3M |
|
17
Vertex Pharmaceuticals
VRTX
$100B
| $32.1M | 1.83% | 293,509 +208,000 | +243% | +$22.7M |
|
18
Regenxbio
RGNX
$451M
| $26.9M | 1.54% | 1,396,244 +113,958 | +9% | +$2.2M |
|
19
Iovance Biotherapeutics
IOVA
$807M
| $26.6M | 1.51% | 3,567,553 | – | – |
|
20
CytomX Therapeutics
CTMX
$336M
| $26.4M | 1.51% | 1,530,659 +606,896 | +66% | +$10.5M |
|
21
AnaptysBio
ANAB
$569M
| $24.5M | 1.39% | +881,957 | New | +$24.5M |
|
|
ZGNX
22
DELISTED
Zogenix, Inc.
ZGNX
| $23.9M | 1.36% | 2,203,302 +1,450,303 | +193% | +$15.7M |
|
23
Ardelyx
ARDX
$1.53B
| $23.9M | 1.36% | 1,886,196 +50,000 | +3% | +$632K |
|
24
Galapagos
GLPG
$2.07B
| $23.4M | 1.33% | 271,405 -33,126 | -11% | -$2.86M |
|
|
DBVT
25
DBV Technologies
DBVT
$264M
| $20.8M | 1.19% | 591,765 -18,878 | -3% | -$665K |
|